FOXY LOCKS LIMITED

Financial Health Score: C- (Borderline Distress)

Explanation: While the patient has a strong heartbeat due to valuable property assets and a history of profitability, it is currently suffering from acute cash flow anemia and a toxic debt structure. The dramatic drop in working capital and the reliance on extremely high-cost short-term financing are severe symptoms of distress, pulling the grade down significantly despite underlying asset strength.

1. Key Vital Signs

• Cash Reserves (Blood Pressure): £145,574 The cash pulse is weakening rapidly. Cash has plummeted from a healthy £704,979 in 2021 to just £145,574 in 2024. This 80% drop over three years indicates the business is struggling to convert sales into liquid cash, leaving it gasping for financial breath.
• Working Capital (Immune System): £409,538 Net current assets (current assets minus current liabilities) have collapsed from a robust £1,789,777 in 2023 to just £409,538 in 2024. This severe contraction means the company's short-term financial immune system is compromised; it has far less buffer to fight off unexpected expenses or dips in revenue.
• Current Liabilities (Cholesterol Levels): £1,583,025 Short-term debts have nearly doubled from £825,101 to £1,583,025. This blockage is primarily caused by swollen trade creditors (£1,036,492, up from £356,894) and high-risk short-term borrowing. This indicates the business is stretching supplier payments to stay afloat.
• Dividends (Blood Loss): £790,000 Despite the deteriorating balance sheet, the company extracted £790,000 in dividends in 2024 (up from £750,000 in 2023). This represents a significant hemorrhage of cash from an already anemic business.
• Net Assets (Overall Body Mass): £679,380 Total net assets have dropped drastically from £1,847,251 in 2023 to £679,380 in 2024. This represents a 63% loss of body mass in a single year, largely driven by the dividend payout and increased liabilities.

2. Diagnosis

Condition: Acute Cash Flow Anemia with Toxic Debt Complications

The financial data reveals a business that is asset-rich but cash-poor, exhibiting classic symptoms of overtrading or cash mismanagement. The underlying health of the business is being severely compromised by two major issues:

1. Toxic Debt Malignancy: The company has resorted to dangerous forms of financing. The accounts reveal a £50,000 drawdown on a facility charging 3% interest per month (equivalent to roughly 42% APR). This is akin to financial poison—while it provides immediate relief, it will rapidly eat away at the business's vitality. Additionally, the company carries long-term loans at 10.5% and 13.7% interest, which are high-cost burdens.
2. Self-Inflicted Hemorrhage: The decision to pay out £790,000 in dividends while cash reserves halved and short-term debt doubled is deeply concerning. Extracting this cash has left the patient dangerously weak, forcing the business to rely on expensive, high-risk borrowing and supplier credit just to maintain daily operations.

The company does possess a strong skeleton in the form of £651,890 worth of freehold property, and it is collecting on a £594,817 Director's Loan. However, property is illiquid, and the Director's Loan represents cash that is currently outside the business rather than inside it where it is desperately needed.

3. Recommendations

To stabilize the patient and restore financial wellness, immediate intervention is required:

1. Stop the Bleeding (Halt Dividends): Immediately suspend all dividend payments until cash flow stabilizes and the business no longer relies on high-cost short-term debt. The £790,000 extracted in 2024 should have been retained to fund working capital and pay down toxic debt.
2. Debt Surgery (Refinance): The 3% per month short-term facility must be excised immediately. Consider refinancing the high-interest long-term loans (10.5% and 13.7%) using the freehold property as security for a traditional, lower-interest commercial mortgage. The property has no mortgage attached in the accounts, making it an excellent candidate for refinancing.
3. Call in Receivables (Transfusion): The Director's Loan of £594,817 must be repaid to the company as a matter of urgency. This cash transfusion would instantly restore the company's working capital to a healthy level and eliminate the need for expensive external borrowing.
4. Inventory Flush: Stock levels remain high at £1,197,673. The business should consider running promotions or clearing slow-moving inventory to convert these idle assets into much-needed cash.
5. Supplier Therapy: The tenfold increase in trade creditors suggests a strained relationship with suppliers. Open dialogue is required to negotiate structured payment plans before supply lines are cut off, which would be fatal to operations.